Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

CancerJun 8, 2026
Clinicopathologic characteristics of early‐onset breast cancer among unselected young Black women

Clinical Context

We think this might be relevant to the clinical guidance for Khorana Score (VTE Risk in Cancer).

CancerJun 5, 2026
Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer

Clinical Context

We think this might be relevant to the clinical guidance for Khorana Score (VTE Risk in Cancer).

JAMAJun 2, 2026
Can Multicancer Detection Blood Tests Save Lives?

Clinical Context

We think this might be relevant to the clinical guidance for Khorana Score (VTE Risk in Cancer).

Khorana Score

KHORANAVTE Risk Assessment in Cancer Patients

Clinical & Lab Factors

Risk Profile

Low Risk

0Points

Prophylaxis Strategy

Score 0. Low risk for VTE. Routine prophylactic anticoagulation is generally not indicated.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Ambulatory cancer patients initiating a new chemotherapy regimen.
To identify patients who should receive prophylactic anticoagulation (e.g., Apixaban or Rivaroxaban).
Validated primarily for solid tumors and some lymphomas.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the CTCAE v5.0, BSA (Mosteller) or the Ecog Status to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

CTCAE v5.0
BSA
CLL-IPI
WHO 2022 / ICC 2022 AML
TNM 9th Ed
FIGO 2023
RANO 2.0
NCCN Prostate Risk
mrTRG
IMWG Myeloma Frailty
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.